The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas.

Autor: See SHC; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: sharlene.see@northwestern.edu., Smith SH; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Finkelman BS; Department of Pathology, University of Rochester School of Medicine, Rochester, NY, USA., LaBoy C; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Novo JE; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Siziopikou KP; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Blanco LZ Jr; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: Pathology, research and practice [Pathol Res Pract] 2023 Jan; Vol. 241, pp. 154299. Date of Electronic Publication: 2022 Dec 31.
DOI: 10.1016/j.prp.2022.154299
Abstrakt: PRAME and NY-ESO-1 are cancer-testis antigens (CTAs) reported to be highly enriched in triple-negative breast cancers (TNBCs), against which vaccines and immunotherapies are currently being developed. This study aims to analyze PRAME and NY-ESO-1 expression in TNBCs and their correlation with clinical outcomes. This is a retrospective cohort study of TNBC patients who have undergone neoadjuvant chemotherapy. PRAME and NY-ESO-1 expression were assessed on pre-therapy biopsies as H-scores (percentage x intensity) with final H scores of 2-3 considered as positive. Association between expression and pathologic complete response (pCR), metastasis, and residual cancer burden (RCB) were assessed via logistic regression. Cox proportional hazards models were used to assess the association with progression-free survival. P-values < 0.05 were considered statistically significant. Sixty-three percent of 76 patients were positive for PRAME. In contrast, only 5 % were positive for NY-ESO-1. PRAME positivity was significantly associated with a lower likelihood of early metastatic disease (OR = 0.24, 95 % CI 0.08-0.62; P = 0.005). However, it was not significantly associated with pCR, RCB category, or progression-free survival. NY-ESO1 score was not significantly associated with early metastatic disease, pCR, RCB category, or progression-free survival. Our results suggest that PRAME positivity may be associated with a lower risk of early metastasis in TNBCs, but not with response to neoadjuvant chemotherapy or progression-free survival. The high expression of PRAME in TNBCs makes it a potential therapeutic target, while NY-ESO1 appears to be a less useful marker. However, further larger studies are needed to ascertain the utility of these markers.
Competing Interests: Declaration of Competing Interest The authors declare no competing interests.
(Copyright © 2023 Elsevier GmbH. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: